🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our new paper on A Clearer Look at Diabetic Kidney Disease today.ucsd.edu/story/a-cleare…

On May 31, we'll explore a variety of tumor types related to bladder and prostate cancers, as well as lymphomas. Register for any of the events. Urothelial Bladder: ow.ly/Qi4T50VTY9E Non Hodgkins Lymphoma: ow.ly/4bVf50VTY9I Prostate: ow.ly/C32S50VTY9K

The brief digital edition of our May issue is live now! Check it out here: mp.weixin.qq.com/s/Ph75nRcl02Hk…

Breaking News: The Trump administration halted Harvard’s ability to enroll international students, a major escalation in its battle with the school. nyti.ms/3SLG7gW

Thanks to @psypost for the thoughtful coverage of our work exploring the neural basis of human decision-making! Explore these findings in further detail in our paper: jneurosci.org/content/45/15/… Learn more about our work: thesaezlab.com

Penn BE PhD student & Schmidt Science Fellow Serena Omo-Lamai, with Dr. Brenner (Penn Medicine) & co-authors explore how RNA–LNPs could transform care for acute critical illnesses. Read in Nature Reviews Bioengineering: go.nature.com/4kofZ7s #RNA #mRNA #Nanoparticles

25 years ago, I came to Stanford on a J1 visa and worked so hard to be worthy of that privilege. Today, I lead Immunology at Mount Sinai and I am the one who feel privileged when brilliant international students chose to join us.

Revoking J1 visas is not only cruel, it undermines trust in American science. As we wrote with Jan Vilcek, an immigrant whose work led to one of medicine’s biggest breakthroughs, J1 students fuel discovery, innovation & US economic growth. cell.com/cell/fulltext/…

Young Scientist Committee YSC-CRS presents #WebinarDuet3: Bringing Innovation into Clinical Impact 🗣️ Join Professors Justin Hanes & Molly Shoichet for a thought-provoking discussion on biomedical innovation 🗓 Thursday, 19th June 2025 | 12 PM EST 🔗goo.su/1yPE18P Controlled Release Society

Science at #UTSW goes deep – down to the nucleic level. Research led by Daniel Siegwart has unlocked synthetic lipid nanoparticles as delivery vehicles for genetic medicines. Explore more in the latest edition of #DiscoveryAtUTSW. bit.ly/43AO6Ej

When are we going to see progress for CAR T in solid tumors?", I'm often asked. More to do for sure, but progress is clear. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial Penn Medicine DrORourke

Everyone should learn to code with AI! At AI Fund, everyone - not just engineers - can vibe code or use AI assistance to code. This has been great for our creativity and productivity. I hope more teams will empower everyone to build with AI. Please watch the video for details.

Building on the success of our existing programs, we’re continuing to advance R&D efforts to help make an impact for patients. Learn about the developments in our rare disease pipeline with insights from Biogen's CEO and leadership team. Register today: ow.ly/3zkR50W3pjx

"The world needs people who leave their comfort zone and explore new domains. It needs people like you, Class of 2025.” - Dean Anantha Chandrakasan, addressing graduates at last week’s School of Engineering and Schwarzman College of Computing Advanced Degree Ceremony

A great article in The Wall Street Journal that highlights the exciting work of Miriam Merad, MD, PhD and her colleagues in identifying the crucial role of "inflammaging" in increasing cancer risk as people age. Icahn School of Medicine at Mount Sinai wsj.com/health/inflamm…

In case you needed a smile this Tuesday: 10-month-old baby KJ, who received a bespoke gene-editing therapy after a six month scientific sprint - "graduated" from the hospital today and went HOME! YAY SCIENCE! Here's his story: wapo.st/451ZQjT

Mount Sinai researchers, in collaboration with the Windreich Department of Artificial Intelligence and Human Health, have developed an AI tool that supports safer, more precise blood sugar management after heart surgery. The model, called GLUCOSE, uses reinforcement learning to

Our lab’s latest publication in Nature Biotechnology led by Minjeong Kim and Daniel Siegwart. Read the full story here: nature.com/articles/s4158…

Excited to see our research led with phenomenal Matthew D. Park, Ph.D. & Tom Marron in The Wall Street Journal ! this builds on years studying inflammation in cancer, now redirected to aging. Now we're launching trials to test if modulating inflammation can prevent age-related diseases.Lipschultz Precision Immunology Institute

OUT NOW➡️the Spring 2025 #FriedmanBrainInstitute newsletter👉reports.mountsinai.org/report/fbispri… In this issue, learn about the promise of GLP-1 agonists for the treatment of drug addiction & the amazing work being done in the Paul Kenny, PhD Lab. reports.mountsinai.org/article/fbispr…